nsc281612 and Carcinoma--Renal-Cell

nsc281612 has been researched along with Carcinoma--Renal-Cell* in 2 studies

Other Studies

2 other study(ies) available for nsc281612 and Carcinoma--Renal-Cell

ArticleYear
Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612).
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:3

    Benzaldehyde dimethane sulfonate (BEN, DMS612, NSC281612) is a bifunctional alkylating agent currently in clinical trials. We previously characterized the degradation products of BEN in plasma and blood. The conversion of BEN to its carboxylic acid analogue (BA) in whole blood, but not plasma, suggests that an enzyme in RBCs may be responsible for this conversion. BEN conversion to BA was observed in renal carcinoma cells and appeared to correlate with IC₅₀. To better understand the pharmacology of BEN, we aimed to evaluate the metabolism and enzymes potentially responsible for the conversion of BEN to BA.. Human red blood cells (RBC) were used to characterize kinetics and susceptibility to enzyme-specific inhibitors. Recombinant enzymes were used to confirm metabolism of BEN to BA. Analytes were quantitated with established LC-MS/MS methods.. Average apparent Vmax and Km were 68 ng/mL min(-1) [10% RBC](-1) and 373 ng/mL, respectively. The conversion of BEN to BA in RBC was not inhibited by carbon monoxide, nitrogen gas, or menadione, an inhibitor of aldehyde oxidase. The conversion was inhibited by disulfiram, an inhibitor of ALDH. Of available ALDH isoforms ALDH1A1, ALDH3A1, ALDH2, and ALDH5A1, only ALDH1A1 converted BEN to BA.. The activating conversion of BEN to BA is mediated not by CYP450 enzymes or aldehyde oxidase, but by ALDH1A1. This enzyme, a potential stem cell marker, may be a candidate biomarker for clinical activity of BEN.

    Topics: Antineoplastic Agents, Alkylating; Benzaldehydes; Carcinoma, Renal Cell; Cell Line, Tumor; Chromatography, High Pressure Liquid; Erythrocytes; Humans; Immunoprecipitation; Kidney Neoplasms

2015
Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1

    Benzaldehyde dimethane sulfonate (BEN, DMS612, NSC281612) is an alkylating agent with activity against renal cell carcinoma and is being evaluated clinically. To support clinical trials, we developed an LC-MS/MS assay to detect and quantitate BEN and its metabolites/decomposition products. We tested the stability and products of BEN and benzoic acid dimethane sulfonate (BA) in plasma, blood and five renal carcinoma cell lines in vitro. Further, we determined the IC(50) of BEN, BA and four of their products in these cell lines. Low temperature and pH stabilized the analytes, and utilizing this resulted in an accurate, precise and reproducible assay. The half-lives of BEN and BA added to plasma in vitro were 220 and 5 min, while the half-life of BEN in whole blood was 18 min. The generation and degradation of up to 12 analytes were monitored, and structures confirmed with available authentic standards. The IC(50) for BEN was 5- to 500-fold lower than that of any of its products, while the cellular metabolic activity toward BEN correlated with ALDH activity and IC(50) values. We detected six of the in vitro products and their respective glucuronides in murine plasma after dosing BEN. The information gained from these experiments will be instrumental in the evaluation of the pharmacology of BEN in ongoing human trials.

    Topics: Aldehyde Dehydrogenase; Animals; Antineoplastic Agents, Alkylating; Benzaldehydes; Carcinoma, Renal Cell; Cell Line, Tumor; Chromatography, Liquid; Female; Glucuronides; Half-Life; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Inhibitory Concentration 50; Kidney Neoplasms; Mesylates; Mice; para-Aminobenzoates; Reproducibility of Results; Tandem Mass Spectrometry; Temperature; Time Factors

2013